Plain-English translation of NCT06349473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a first-in-human study testing , a new injectable medication designed to help people with bleeding disorders. The trial has two parts: Part A tests the medication in healthy volunteers to make sure it's safe, and Part B tests it in people who actually have hemophilia A, hemophilia B, or Factor VII deficiency to see if it works and is tolerated well.
People with severe hemophilia and Factor VII deficiency currently rely on frequent treatments or prophylaxis to prevent dangerous bleeding. This trial is exploring whether this new medication could offer a better or more convenient treatment option for these life-threatening bleeding disorders.
You likely qualify if…
You likely don't qualify if…
If you're in Part A (healthy volunteer), you'll receive a single injection on Day 1 and then have follow-up visits and blood tests over about 3 months. If you're in Part B (with a bleeding disorder), you'll receive injections every 4 weeks over the same roughly 3-month period, with regular check-ins and blood work to monitor how the medication affects your bleeding episodes. All participants will need to complete physical exams, heart monitoring, and lab tests throughout the study.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States